Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.

@article{Wirth2017SofosbuvirAR,
  title={Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.},
  author={Stephan Wirth and Philip J. Rosenthal and Regino P. Gonz{\'a}lez-Peralta and Maureen M. Jonas and William F. Balistreri and C H Lin and Winita Hardikar and Kathryn Kersey and Benedetta Massetto and Bittoo Kanwar and Diana M. Brainard and Jiang Shao and Evguenia S. Svarovskaia and Brian J Kirby and Ronen Arnon and Karen F. Murray and Kathleen B. Schwarz},
  journal={Hepatology},
  year={2017},
  volume={66 4},
  pages={1102-1110}
}
Children with chronic hepatitis C virus infection have limited treatment options. We evaluated the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with hepatitis C virus genotype 2 or 3 (ClinicalTrials.gov NCT02175758). Fifty-two patients received sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks. The pharmacokinetics of sofosbuvir and its metabolite GS-331007 were evaluated by intensive plasma sampling at… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
12 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Treating HCV infection in children

  • CK Lee, MM Jonas
  • Clinical Liver Disease
  • 2015

Similar Papers

Loading similar papers…